Ionis Pharmaceuticals (IONS) said results from a late-stage study of pelacarsen are expected in H1 2026 after a data readout from the phase 3 trial had been expected from drug development partner Novartis (NVS) this year.
"This update is based on the accrual rate of blinded events in the ongoing Phase 3 Lp(a)HORIZON
event-driven cardiovascular outcomes study that Novartis is conducting in more than 8,000 patients," Ionis said Friday in a statement.
Ionis said the companies expect to seek regulatory approval of the medicine in H2 2026.
"Ionis remains confident in pelacarsen and the Lp(a)HORIZON study and its potential to show benefit in patients with cardiovascular disease and high Lp(a)," according to the statement.
Ionis licensed the drug to Novartis in 2019.
Ionis shares fell 0.8% recent Friday trading, and Novartis rose 0.3%.
Price: 33.06, Change: -0.26, Percent Change: -0.77
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。